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Abstract: In an era of improved survival due to modern antiretroviral therapy, liver disease has become
a major cause of morbidity and mortality, resulting in death in 15–17% of human immunodeficiency
virus (HIV)-infected patients. Alcohol enhances HIV-mediated liver damage and promotes the
progression to advanced fibrosis and cirrhosis. However, the mechanisms behind these events
are uncertain. Here, we hypothesize that ethanol metabolism potentiates accumulation of HIV in
hepatocytes, causing oxidative stress and intensive apoptotic cell death. Engulfment of HIV-containing
apoptotic hepatocytes by non-parenchymal cells (NPCs) triggers their activation and liver injury
progression. This study was performed on primary human hepatocytes and Huh7.5-CYP cells
infected with HIV-1ADA, and major findings were confirmed by pilot data obtained on ethanol-fed
HIV-injected chimeric mice with humanized livers. We demonstrated that ethanol exposure potentiates
HIV accumulation in hepatocytes by suppressing HIV degradation by lysosomes and proteasomes.
This leads to increased oxidative stress and hepatocyte apoptosis. Exposure of HIV-infected apoptotic
hepatocytes to NPCs activates the inflammasome in macrophages and pro-fibrotic genes in hepatic
stellate cells. We conclude that while HIV and ethanol metabolism-triggered apoptosis clears
up HIV-infected hepatocytes, continued generation of HIV-expressing apoptotic bodies may be
detrimental for progression of liver inflammation and fibrosis due to constant activation of NPCs.
Keywords: human immunodeficiency virus; hepatocytes; ethanol; acetaldehyde; apoptotic bodies;
inflammation; fibrosis
1. Introduction
Several hepatobiliary disorders, as well as overt liver injury, are associated with human
immunodeficiency virus (HIV) infection. In an era of improved survival due to modern antiretroviral
therapy (ART), liver disease has become a major cause of morbidity and mortality among HIV-infected
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persons, resulting in death in 15–17% of HIV-infected patients [1]. Modern ART efficiently blocks
active HIV replication in HIV-permissive cells but does not eliminate latently infected cells that have
HIV-DNA integrated into the host genome, thereby improving disease outcomes without halting
liver disease progression [2]. The recognition of HIV-induced liver injury as an important clinical
manifestation was supported by many clinical studies [3–5], with special emphasis on association
between HIVRNA content and liver fibrosis development [6,7]. While HIV monoinfection by itself
elevates liver transaminase levels, the exacerbation of liver injury is even more prominent when HIV
patients are either co-infected with hepatotropic viruses, hepatitis C virus (HCV), and hepatitis B virus
(HBV), or are exposed to liver-damaging substances such as alcohol [8]. These insults serve as the
potent second hits in acceleration of HIV-induced liver disease [1,9,10].
Alcohol is a potent trigger of HIV-mediated liver damage, which frequently ends in progression to
advanced fibrosis and cirrhosis [10,11]. The mechanisms behind these events are uncertain. They may
be partially attributed to changes in gut microbiota and enhanced gut leakage induced by both
HIV and alcohol, causing liver non-parenchymal cells activation via the Toll-like receptor (TLR) 4
pathway [12,13]. However, HIV-alcohol-mediated liver disease is not limited only to one mechanism.
Furthermore, while HIV interaction with multiple hepatic cell types, including Kupffer cells (KCs) and
hepatic stellate cells (HSCs), has been already reported [14–16], the detailed evaluation of HIV infection
in hepatocytes as well as mechanisms by which ethanol metabolism triggers liver inflammation and
fibrosis require further clarification.
Although liver injury in HIV patients was previously attributed to ART-related hepatotoxicity [17]
and that now new medications without significant hepatotoxic properties have become available [18],
it is clear that HIV by itself may induce hepatocyte death. The ability of HIV to trigger apoptosis
is well-documented in CD4+ lymphocytes [19]. However, other studies indicate that apoptosis
predominantly occurs in bystander, not productively infected, lymph node cells [20]. To our knowledge,
the effects of ethanol metabolism on HIV-induced apoptosis of hepatocytes as well as its relation to
infection of these cells with HIV had not been investigated. Hepatocytes are major sites of ethanol
metabolism and comprise 80% of liver cells. Thus, the pro-apoptotic effects of HIV potentiated by ethanol
metabolism are crucial for liver injury even in the absence of ART. Here, we hypothesize that ethanol
metabolism potentiates accumulation of HIV in hepatocytes, causing oxidative stress and intensive
apoptotic cell death. Engulfment of HIV-containing apoptotic hepatocytes by non-parenchymal cells
promotes their activation and liver injury progression. Our findings indicate that ethanol metabolism
and mainly, acetaldehyde (Ach) enhances accumulation of HIV-related components in hepatocytes
due to their impaired degradation by lysosome and proteasome. Combined with Ach, these HIV
components induce oxidative stress, abortive HIV infection of hepatocytes, and apoptotic cell death.
Engulfment of hepatocyte apoptotic bodies (ABHep) by liver macrophages (Mph )and HSCs promotes
pro-inflammatory and pro-fibrotic change development.
2. Materials and Methods
2.1. Reagents and Media
High glucose Dulbecco’s Modified Eagle Medium (DMEM) and fetal bovine serum were purchased
from Invitrogen (Carlsbad, CA, USA), Trizol was sourced from Life Technologies, primer probes and
reverse transcription polymerase chain reaction (RT-PCR) reagents were from Applied Biosystems by
Thermo Fisher Scientific, (Ashveville, NC, USA). Anti-CYP2E1 was from EMD Millipore (Temecula,
CA, USA). Other reagents, all analytical-grade quality, were from Sigma (St. Louis, MO, USA).
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2.2. Cells and Treatments
We used human primary hepatocytes obtained from the Liver Tissue Cell Distribution System
(Minneapolis, MN; Pittsburgh, PA; NIH Contract #HSN276201200017C). HIV was purified as described
in [21]. Cells were either infected with HIV-1ADA (multiplicity of infection, MOI 0.1) for three days or
with HIV combined with 50 mM ethanol treatment. We established the optimal regimen for EtOH
treatment in HIV-infected hepatocytes to induce the highest apoptosis levels. In this regard, primary
hepatocytes were either pre-treated with EtOH for 24 h before HIV-infection (pre-treatment), treated for
the last 48 h of infection (post-treatment), or pre- and post-treatment regimens were combined. Since
hepatocytes plated on collagen undergo fast de-differentiation and lose Cytochrome P4502E1 (CYP2E1)
and Alcohol Dehydrogenase (ADH) expression in 24 h [22], and because the sustained expression of
these ethanol-metabolizing enzymes is necessary for successful ethanol treatment, cells were plated on
custom soft gels (polyelectrolyte multilayer (PEM) film coating on top of the polydimethyl siloxane
surface, two-dimensional (2D) culture) to support long-term cell functionality (described in [23]).
Due to limited availability of human hepatocytes, for their experimental prototype we also used
Huh7.5-CYP (RLW) cells. These cells have reduced innate immunity and can be infected with HIV.
They were stably transfected to metabolize ethanol by CYP2E1, but do not express ADH. To overcome
this limitation, we treated RLW cells with an acetaldehyde-generating system (AGS), which contains
yeast ADH as a source of enzyme, nicotinamide adenine dinucleotide (NAD) as a co-factor, and 50 mM
ethanol (EtOH) (substrate for ADH), and continuously produces physiologically relevant amounts of
acetaldehyde (Ach) without toxic effects. We have characterized and successfully used these cells and
AGS for HCV-based ethanol in vitro studies [24,25]. The downstream effects of AGS were validated by
experiments on ethanol-treated primary hepatocytes.
Pancaspase inhibitor (PCI) from Ubiquitin-Proteasome Biotechnologies (UBPBio) Inc. (Cat#F7110,
Aurora, CO, USA) was used at 10 µM for the duration of HIV + EtOH treatment. Proteasome inhibitors
MG132 (Cat#F1100; 5 µM overnight) and carfilzomib (Cat#F1300; 100 nM overnight) from UBPBio,
Inc. (Aurora, CO, USA), and lysosome inhibitors bafilomycin (Sigma; #B1793; 50 nM overnight) and
chloroquine (Sigma; #C6698; 5, 20, 50 µM overnight) were used in this study. The HIV replication
inhibitor azidothymidine (AZT) was used at a 100 mM concentration during HIV + EtOH treatment.
2.3. Human Monocyte-Derived Macrophages
Monocytes were obtained from healthy donor blood elutriation. Monocyte suspensions were
documented as 98% pure by criteria of cell morphology in Wright-stained cytosmears. Monocytes
were cultured in 48-well plates (2 × 105 cells/well) in DMEM (Sigma) with 10% heat-inactivated pooled
human serum, 1% glutamine, 50 g/mL gentamicin, and/or 10 g/mL ciprofloxacin (Sigma) and human
CSF-1. Culture medium was changed every three days. All tissue culture reagents were screened
and found negative for endotoxin (10 pg/mL; Associates of Cape Cod, Woods Hole, MA, USA) and
mycoplasma contamination (Gen-Probe II; Gen-Probe, San Diego, CA, USA). After seven days in
culture, monocyte-derived macrophages (MDMs) were used for experiments.
2.4. Hepatic Stellate Cells (HSCs)
As the source of human hepatic stellate cells (HSCs), we used commercially available human cell
line LX2 (EMD Millipore, cat SCC064) grown based on instructions from the manufacturer.
2.5. Apoptotic Body (AB) Generation and Treatment Macrophages and Hepatic Stellate Cells with Apoptotic
Hepatocytes
To mimic apoptosis triggered by EtOH metabolism in HIV-infected hepatocytes, HIV-infected and
non-infected cells were exposed to UV light (0–100 mJ/cm2, 140 s) to make ABHep. In 24 h, ABs were
collected from supernatant by pelleting the cells at 1500 rpm for 5 min and re-suspended in DMEM.
They were exposed to MDMs and LX2-cells at a 3:1 ratio as previously described [26].
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2.6. RNA Isolation, Real-Time Polymerase Chain Reaction, and Western Blotting
Human immunodeficiency virus-RNA (HIV RNA), interferon-stimulated genes (ISGs) with
anti-viral activities such as ISG15, 2′-5′-oligoadenylate synthetase 1 (OAS1), inflammasome markers
NLR family pyrin domain containing 3 (NLRP3), caspase-1, Interleukin (IL)-1β, and IL-18, and pro-fibrotic
markers collagen 1 A1 (Col1A1), transforming growth factor beta (TGFβ), and prostaglandin D receptor
2 (PTGDR2) were quantified by real-time PCR as previously described [27]. Total RNA was isolated
from cells using Trizol Reagent. A two-step procedure was used, in which 200 ng RNA were
reverse-transcribed to cDNA using the high capacity reverse transcription kit. In the second step, the
cDNA was amplified using TaqMan Universal Master Mix-II with fluorescent-labeled primers (TaqMan
gene expression systems). These were incubated in a Model 7500 qRT-PCR thermal cycler. The relative
quantity of each RNA transcript was calculated by its threshold cycle (Ct) after subtracting that of the
reference cDNA (GAPDH) as described before [27]. Reverse transcriptase (RT) activity was detected in
cell supernatants as described [28]. For Western blotting (WB), cell lysates were prepared in 0.5 M
ethylenediaminetetraacetic acid (EDTA), 2 M Tris, 20 mM sodium orthovanadate (Na3VO4), 200 mM
tetrasodium pyrophosphate (Na4P2O7), 100 mM phenylmethylsulfonyl fluoride (PMSF), 1 M NaF, 20%
Triton X-100, and aprotinin, pH = 7. Samples were subjected to denaturing sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) in polyacrylamide gels. Western blot was performed
as described previously [27], blots were developed using Odyssey® infrared imaging system (Li-Cor
Bioscience, Lincoln, NE, USA), and the protein band was quantified using Li-Cor software. The B-actin
was used as the loading control to normalize the proteins.
2.7. Total HIV-1 DNA Quantification Using Semi-Nested Polymerase Chain Reaction
Total genomic DNA (gDNA) was isolated from RLW cells using the DNeasy Blood & Tissue Kit
(Qiagen, Germantown, MD, USA) according to the manufacturer’s protocol. Semi-nested real-time
PCR was performed as described earlier and included two rounds of PCR amplification of the HIVgag
region [29]. The ACH2 cells DNA was used to construct a dilution series ranging from 105 to 10 DNA
copies per sample.
2.8. Integrated HIV-1 DNA Quantification Using Digital-Droplet PCR (ddPCR)
For the evaluation of integrated HIV DNA, isolated gDNA was digested with restriction
endonuclease enzyme and amplified with a first-round PCR amplification (95 ◦C for 2 min; 20 cycles of
95 ◦C for 15 s, 50 ◦C for 15 s, and 72 ◦C for 150 s) using 100 nM alu (GCCTCCCAAAGTGCTGGGATTACA)
and 600 nM gag reverse primers GTTCCTGC TATGTCACTTCC), as described previously [29].
Further, the product of first PCR was quantified for integrated DNA by the ddPCR method.
Briefly, the final PCR reaction was comprised of ddPCR supermix (Bio-Rad), 900 nM primers (sense
5′-TCAGCCCAGAAGTAATACCCATGT-3′ and antisense 5′-CACTGTGTTTAGCATGGTGTTT-3′),
a 250 nM probe (FAM-ATTATCAGAAGGAGCCACCCCACAAGA3-ZEN/Iowa Black FQ), and 4 uL
of first PCR product in a final volume of 20 µL, and loaded into an eight-channel disposable droplet
generator cartridge (Bio-Rad). Generated droplets were then transferred into a 96-well PCR plate,
heat-sealed with foil, and then amplified to endpoint using a BioRad C1000 Touch PCR cycler at 95 ◦C
for 10 min, then 40 cycles of 94 ◦C for 15 s, and 60 ◦C for 1 min (2 ◦C/s ramp rate) with a final step at
98 ◦C for 10 min and a 4 ◦C hold. Plates containing amplified droplets were loaded into a QX200
droplet reader (Bio-Rad), as described previously [30]. Discrimination between negative droplets (no
integrated copies) and positives (with HIV-integrated DNA) was used to estimate concentration of
targets (HIV integrated copies) using QuantaSoft analysis software (Bio-Rad). The resulted copies
were normalized to input RNA and represented as integrated DNA copies per µg of DNA.
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2.9. Activities of Proteasome and Cathepsins
Proteasome chymotrypsin-like and trypsin-like activities were determined as previously
reported [31] using cell lysates as the source of the enzyme in 0.1 M Tris–HCl (pH 7.5) and a
final concentration of 13.3 µM N-succinyl-leu-leu-val-tyr-7-amido-4-methlycoumarin (suc-LLVY-AMC;
UBPBio, Inc.) for measurement of chymotrypsin-like activity, and boc-leu-ser-thr-arg-7-amido-
4-methlycoumarin (boc-LSTR-AMC; UBPBio Inc) to detect trypsin-like activity in a 200 µL reaction
mixture using 96-well black bottom plates. Samples were incubated for a total of 60 min at 37 ◦C and
during that period, read every 15 min on a spectramax plate reader at 355 nm (excitation) and 460 nm
(emission), top read. Standard curve was generated based on known quantities of AMC (Sigma).
Specific activity was expressed as nmols AMC/mg protein.
Cathepsin B and L activities were assayed in cell lysates using specific fluorogenic peptide
substrates, Z-arg-arg-7-amido-4-methylcoumarin hydrochloride (cathepsin B) and L-phe-arg-7-
amido-4-methylcoumarin hydrochloride for cathepsin L, as described [32]. All samples were incubated
at 37 ◦C for 20 min and fluorescence was measured every 5 min using a spectramax plate reader.
Fluorescence of 7-amino-4-methylcoumarin (AMC) was measured at 370 nm (excitation) and 460 nm
(emission), top read. Known quantities of AMC (Sigma) were used as standards.
2.10. Validation of In Vitro Results by In Vivo Studies
For confirmation purposes, we used TK-NOG mice initially provided by Dr. Mamoru Ito,
CIE, Japan and then bred at Animal Facility, UNMC, Omaha, NE. The protocol of experiments
was approved by the UNMC Animal Studies Committee. Transgenic expression of herpes simplex
virus thymidine kinase under albumin (Alb) promoter allows for conditional depletion of mouse
hepatocytes after ganciclovir administration, which supports the expanding of transplanted human
hepatocytes. We used only transgenic males that can be successfully transplanted with human
hepatocytes. After aproximately four months post-transplantation, liver humanization was detected
by the presence of human Alb quantified by enzyme-linked immunosorbent assay ELISA (Alb
concentration 0.5–2.0 mg/mL). Mice (three mice per group) were pair-fed control and EtOH (5% v/v)
Lieber De Carli diets for 10 days, then gavaged with phosphate buffer solution (PBS)/maltose dextran
or EtOH on day 11 and sacrificed 9 h after gavaging, as described in detail for an chronic-acute NIH
EtOH model [33]. Every other day during this feeding period they were intraperitoneally (IP)-injected
with HIV-1ADA or left uninfected.
2.11. Statistical Analyses
Data from at least three duplicate independent experiments are expressed as mean values ±
standard error. Comparisons among multiple groups were determined by one-way ANOVA, using a
Tukey post-hoc test. For comparisons between two groups, we used Student’s t-test. A probability
value of 0.05 or less was considered significant.
3. Results
3.1. Ethanol Promotes Apoptosis in HIV-Infected Hepatocytes
We established the optimal regimen for EtOH treatment in HIV-infected hepatocytes to induce the
highest apoptosis levels. In this regard, primary hepatocytes were either pre-treated with EtOH for
24 h before HIV-infection (pre-treatment) or treated for the last 48 h of infection (post-treatment), or
pre- and post-treatment regimens were combined. Figure 1A shows that the highest caspase 3 cleavage
was obtained with the combined treatment.
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Fig re 1. Human immunodefeciency virus ( I ) and ethanol in ce a o tosis in he atocytes: ata
are fro three independent experiments presented as means ±standard error, (SE). Bars marked
with the same letter are not significantly different from each other; bars with different letters are
significantly different (p ≤ 0.05). ( ) Effects of various Et treat ent regi ens on caspase 3 cleavage
in HIV-exposed hepatocytes (Western blotting, WB). (B) Prolonged expression of alcohol-metabolizing
enzymes, CYP2E1 and ADH, in hepatocytes plated on polyelectrolyte multilayer (PEM) gels. We cut a
unnecessary group in third lane, so we joined the last lane. (C) M30 ELISA (apoptosis) in HIV-infected
hepatocytes in the presence or absence of azidothymidine (AZT) (100 µM). (D) Effects of various HIV
MOI on caspase 3 cleavage in RLW cells treated with an acetaldehyde-generating system (AGS).
Plating hepatocytes on PEM soft gel allowed prolonged (up to six days) expression of
ethanol-metabolizing enzymes during the time of ethanol exposure, and the combined EtOH treatment
induced the stabilization of CYP2E1, but not ADH proteins in these cells (detected by WB, Figure 1B).
Thus, for further experiments, we used the combined treatment of HIV-infected cells with EtOH
(designated as HIV + EtOH). These caspase-3 cleavage results were confirmed by M30 ELISA
demonstrating 4-fold potentiation of apoptosis in HIV-infected cells by EtOH, which was attenuated
by azidothymidine (AZT) co-treatment (Figure 1C). A similar pattern was observed in an experimental
prototype of hepatocytes, CYP2E1-expressing Huh7.5 (RLW) cells infected with various MOI of HIV
and exposed to AGS (Figure 1D). The increase in caspase-3 cleavage by AGS was HIV-dose-dependent.
3.2. HIVgag Expression in Hepatocytes Exposed to Ethanol/AGS
Human immunodefeciency virus (HIV)-dose dependence of caspase-3 cleavage and the
suppression of HIV-EtO -induced apoptosis by AZT suggests the link between HIV infection
of hepatocytes and their ability to undergo apoptosis. Thus, we measured the effects of EtOH on
HIVgag RNA expression (RT-PCR) and found a 2.5-fold increase by exposure to EtOH. Since in
previous experiments we observed apoptosis under these treatment conditions, we screened for
HIVgag RNA levels in hepatocytes exposed to pan-caspase inhibitor (PCI) (Figure 2A). The protection
of cells from apoptosis by PCI significantly upregulated the expression of HIVgag RNA, indicating
that infected cells undergo apoptosis. This increase was attributed to ethanol metabolism since
ethanol metabolism inhibitor, 4-methyl pyrazole (4MP) reversed the effects of ethanol on HIVgag RNA
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expression (Figure 2B). Ethanol only slightly enhanced low levels of reverse transcriptase (RT) activity
in hepatocyte supernatants (Figure 2C) as well as in RLW cells exposed to HIV and AGS (Figure 2D).
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Figure 2. Effects of ethanol metabolism on human i munodeficiency virus gag ribonuclear acid
( IVgag RNA) expression in HIV-infected hepatocytes. All data are from three independent experiments
presented as means ± SE. Bars marked with the same letter are not significantly different from each
other; bars with different letters are significantly different (p ≤ 0.05). (A) Effects of pancaspase inhibitor
(PCI) on HIV gag RNA in primary human hepatocytes. (B) Effects of (AZT and 4-methyl pyrazole (4MP)
on HIV RNA in primary human hepatocytes. (C) Reverse transcriptase (RT) activity in supernatants of
primary human hepatocytes. (D) RT activity in supernatants of RLW cells exposed to AGS. (E) The
HIVgag RNA after removal of membrane-expressed structures by low acid wash in RLW cells.
To exclude the possibility that HIV RNA comes from the viral particles attached to cell membrane,
we treated HIV-infected RLW cells with AGS and then removed the membrane-associated binders
by low acid stripping [34]. There was no reduction in HIVgag RNA by acid wash in cells protected
from apoptosis with PCI (Figure 2E), indicating that HIVgag RNA detected in EtOH/AGS-treated
cells is inside of cells, and thus, ethanol metabolism (mainly Ach) enhances intracellular expression of
HIVgag RNA.
3.3. Effect of AGS on HIV DNA Levels in RLW Cells
The HIV DNA was measured in the presence or absence of PCI. For these experiments, RLW
cells were infected with HIV in the presence or absence of AGS and PCI. HIV DNA with AGS (pre- or
combined treatment ) was detected in RLW cells in the presence of PCI. The number of detectable copies
in RLW cells was measured by q-PCR. We found that AGS significantly (up to 300-fold) increased HIV
DNA levels only when cells were expesosed to PCI (Figure 3A). Furthermore, AGS (both pre-treatment
and combined treatment) increased the integration of HIV DNA into the cell’s genome, with the highest
affects on day 3 post-infection, while at day 5 post-infectiction, less integrated HIV DNA was observed
(Figure 3B).
Biomolecules 2019, 9, 851 8 of 19
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Figure 3. Effect of acetaldehyde generating system (AGS) on HIV-DNA levels in RLW cells. The results
from duplicated representativ xperiment are shown in panels (A,B). (A) Effects of PCI on intracellular
HIV DNA. (B) AGS increased the level of int grat d HIV DNA (in he presence of PCI).
3.4. Kinetics of HIV Markers in RLW Cells in Response to AGS Treatment
To elucidate the kinetics of HIV infection in RLW cells and its connection to apoptosis, we measured
the levels of HIVgag RNA and p24, adduction of cell proteins with 4-hydroxynonenal (4-HNE), and
reactive oxygen species (ROS) release (2′, 7′-dichlorofluorescein fluorescence method, DCF) as well as
cleaved caspase-3 at days 1, 3, and 5 post-infection (Figure 4).
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The experiments were one after one-day pretreatment of HIV-infected RLW cell with AGS in the
presence of PCI (exce t for the set of cells f r cleaved caspase-3 detection). While all tested parameters
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were at significantly higher levels in AGS-treated HIV-infected cells versus HIV-infected cells, the
highest levels of HIV RNA and p24 were detected at day 1 post-infection, with further decrease by day
5 (p < 0.05) (Figure 4A,B) The kinetics of oxidative stress markers, ROS and 4-HNE-adducted protein
expression, as well as cleaved caspase-3 were the opposite: we observed their increase from day 1 to
day 5 of HIV-infection (p < 0.05). (Figure 4C–E). The levels of pro-caspase-3 were not changed.
3.5. Possible Mechanisms of Up-Regulation of HIV Expression by Ethanol Metabolites
3.5.1. Receptors for Viral Entry
In the next set of experiments, we tested a sub-hypothesis that ethanol metabolism up-regulates
HIV RNA and p24 in hepatocytes due to AGS-enhanced expression of receptors for HIV entry. Since
hepatocytes/hepatoma cells are CD4-negative cells, by flow cytometry we measured the effects of AGS
on expression the candidate receptors for HIV entry on hepatocytes, namely, CXCR4, CCR5 and GalCer
(galactosyl ceramide). The RLW cells were treated with AGS for 48 h and then expression of CXCR4,
CCR5 and GalCer was detected by flow cytometry using directly labeled antibodies. As it appeared,
AGS exposure to RLW cells provided minimal effects on expression of these receptors (Figure 5A–C).
The highest up-regulative effect of AGS (both on % of positive cells and brightness) was observed with
CXCR4 receptor reported before as a receptor for HIV entry on hepatocytes [35].Biomolecules 2019, 9, x FOR PEER REVIEW 10 of 20 
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3.5.2. HIV-Accumulation in Hepatocytes Due to AGS-Suppressed Degradation
As another option, we cannot exclude that after HIV enters hepatocytes, its components undergo
degradation by major intracellular degradation enzymes, lysosomes and proteasomes, whose activities
may be suppressed by ethanol metabolism and by exposure to AGS [31,36]. To mimic this situation,
we treated HIV-infected cells with the lysosome inhibitor, chloroquine, which dose-dependently
increased HIV RNA levels in RLW cells (qPCR, Figure 6A). Then we studied whether the higher
levels of HIV p24 expression in AGS-exposed cells (vs. HIV-infected RLW cells non-treated with
AGS) detected at day 3 can be mimicked by cell exposure to the lysosome inhibitor bafilomycin or
to the proteasome inhibitors MG132 and carfilzomib applied to cells one day before cell harvesting.
We indeed observed stabilization of p24 by cell exposure to either lysosomal (a 4.6-fold increase)
or proteasomal inhibitors (a 2.3-fold increase) (Figure 6B). Furthermore, HIV combined with AGS
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suppressed chymotrypsin-like and trypsin-like proteasome activities as well as activities of cathepsin
L and B in RLW cells (Figure 6C–F).Biomolecules 2019, 9, x FOR PEER REVIEW 11 of 20 
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3.6. Ethanol Metabolism-Induced Gene Activation in HIV-Infected Hepatocytes
Since the levels of HIV RNA, p24 and HIV DNA were increased by exposure of cells to ethanol/AGS,
we studied whether these treatments affected qualitative characteristics of hepatocytes, namely, gene
activation profile tested by Next Generation Sequencing (NGS, DEG log2 fold change HIV vs. control
and HIV + EtOH vs. control). As shown on Figure 7A, EtOH upregulates the expression of multiple
genes that encode stress response (THBS1, MT1A, CXCL13, TSC22D3, USP43, FKBP5, CPEB4, ERRFI1)
in hepatocytes.
In RNA-seq experiment (NGS), we estimated HIV gene expression levels by the abundance of
mapped to HIV genome transcripts from unmapped to human genome. HIV reads were not found
in uninfected control and EtOH samples. Reads of Vif were found only in HIV + EtOH-treated
hepatocytes. Also, under ethanol treatment of hepatocytes, we detected increased HIV genes such
as Vpr expression (Figure 7B) belonging to interferon-stimulated genes (ISG). In this regard, we
additionally tested the effects of HIV and AGS exposure to RLW cells on IFNα-induced anti-viral ISGs,
OAS1, and ISG15, as well as on the pro-apoptotic genes TRAIL-R2 and p53. ISGs were quantified
by RT-PCR in non-infected and HIV infected RLW cells treated in the presence or absence of AGS
and IFNα (200 IU for the last 18 h). The combination of HIV and AGS suppressed OAS1 and ISG15
genes (Figure 7C). AGS and its combination with HIV increased the expression of TRAIL-R2 and p53
compared with uninfected and HIV-infected cells due to the up-regulative effects of AGS (Figure 7D).
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Figure 7. Gene activation in hepatocytes exposed to HIV and EtOH. Data are from three independent
experiments presented as means ± SE. Bars marked with the same letter are not significantly different
from each other; bars with different letters are significantly different (p ≤ 0.05): (A) Next-generation
sequencing (NGS, heatmap); (B) Expression of HIV genes (NGS); (C) Activation of interferon-stimulated
genes (ISGs) in RLW cells. (D) Activation of pro-apoptotic genes in RLW cells.
3.7. Hepatocyte-Derived Apoptotic Bodies (ABHep) and HIV Infection
Although HIV- inf c ion in hepatocytes is not productive, we observed intensive apoptosis in
HIV-infected cells treated with AGS. This apo tosis leads to prominent ABHep f rmatio . Here,
we asked the question as to whether this ABHep formation from i fected hepatocytes is beneficial
or harmful for the liver. To mimic pro-ap ptotic eff cts of AGS treatment, we generated ABHep
from uninfected and HIV-infected RLW cells (apoptotic bodies control (ABcntr) and apoptotic bodies
HIVinfected (ABHIV)) as described and characterized earlier [25]. These ABHep were incubated with
MDMs for two hours and then inflammasome activation was measured based on NLRP3, caspase-1,
IL-1β, and IL-18 mRNA expressions. We observed the induction of all these mRNAs by engulfment of
ABHIV (compared with ABcntr) (Figure 8A).
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Furthermore, this effect of ABHIV was abrogated by the treatment of infected RLW cells with HIV
inhibitors, AZT, or raltegravir (RLV) before ABHIV generation.
Since HSCs can also engulf AB, which promotes their survival [37], we exposed HSC (LX2 cells) to
ABcntr or ABHIV and then measured the induction of the pro-fibrotic markers collagen1 A1 (Col1A1),
TGFβ, and prostaglandin D receptor 2 (PTGDR2) in HSCs. In all cases, there was a 2–2.5-fold increase
in pro-fibrotic markers expression in response to ABHIV (compared with engulfment of ABcntr,
Figure 8B). To elucidate whether pro-fibrotic activation of HSCs by ABHIV is hepatocyte-specific, in
addition to ABHep, we generated ABs from HIV-infected and uninfected (control) human lymphocytes
and exposed them to HSC. Unlike ABs of hepatocyte origin, engulfment of ABs from HIV-infected
lymphocytes (ABlyHIV) induced pro-inflammatory activation (Figure 8C) but suppressed Col1A1 and
TGFβ gene activation (Figure 8D) in LX2 cells.
3.8. In Vivo Effects of HIV and Ethanol on Human Hepatocytes
To confirm our in vitro findings by in vivo experiments, we used TK-NOG mice. The TK-NOG
males were transplanted with human hepatocytes at 10 weeks of age. Three months later the levels of
human albumin (Alb) stabilized at 1.1–2.5 mg/mL. Then animals were fed control and ethanol diets as
described [33]. During 10 days of pair-feeding, mice were injected with 3 × 105 TCID50 HIV-1 i.p. every
two days. Last injection was done 24 h before euthanasia. As shown in Figure 9A–D, there was human
albumin reduction in the HIV + EtOH group of mice. This depletion was accompanied by the activation
of oxidative stress (thiobarbituric acid reactive substances, TBARS, activity kit, Cayman Chemicals,
Ann Arbor, MI, USA). While the number of human hepatocytes was significantly decreased based
on human-specific Ki-67 and CK-18 staining, there were still residual caspase-3-positive (apoptotic)
hepatocytes in this group not fully cleared by liver non-parenchymal cells during the feeding period.
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4. Discussion
The liver plays a major role in the clearance of circulating viral particles in the blood, as shown
for the simian immunodeficiency virus [38]. As demonstrated earlier, while hepatocytes appear
to be non-permissive when affected by HIV monoinfection, their exposure to the HIV combined
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with second hits (HCV co-infection) may lead to increased cell death [23,39]. Here, we investigated
whether HIV infects hepatocytes and if the combined insult of HIV with ethanol metabolism causes
apoptotic cell death in hepatocytes. We believe that the studies on the role of ethanol metabolism in
HIV-induced hepatocyte death are crucial for understanding of detrimental end-stage liver disease
outcomes triggered by second hit-induced apoptosis in HIV-infected hepatocytes.
As evident from the experiments on both primary human hepatocytes exposed to ethanol and RLW
(Huh7.5-CYP) cells treated with Ach generated by AGS, HIV-dependent induction of apoptosis was
attenuated by AZT (HIV reverse transcriptase inhibitor) co-treatment. In fact, apoptosis was enhanced
with increasing MOI of HIV in the cells exposed to AGS, indicating the causative link between the
expression of HIV in hepatocytes and apoptotic cell death. In fact, the ability of HIV antigens, namely
gp120, to promote apoptosis in hepatocytes has been reported previously [40]. This apoptosis was
caspase-independent [41] and was triggered via CCR5 and CXCR4 receptors on hepatocyte surface
by gp120 [41,42], which does not require intracellular expression of HIV. However, in our case, when
hepatocytes were infected with HIVADA, pan-caspase inhibitor suppressed the depletion of HIV RNA
levels in AGS-treated cells, indicating its caspase dependence. In addition, the removal of surface cell
structures by low acid wash did not reverse an increase in HIV RNA by AGS, suggesting that the
observed upregulation of HIV RNA was attributable to the intracellular presence of HIV in hepatocytes
but not to HIV attachment to cell membrane.
How does acetaldehyde increase HIV levels in hepatocytes and thereby contribute to apoptosis?
We found that besides HIV RNA and p24 expression, integrated HIV DNA was increased by AGS
treatment. Since we were able to measure integrated HIV DNA only by very sensitive method of
ddPCR, we would assume that AGS-induced HIV DNA integration into host genome is extremely low
in hepatocytes. In addition, AGS treatment up-regulated integrated HIV DNA only in the presence of
PCI, indicating that AGS- and HIV-induced caspase-dependent apoptosis clears up infected hepatocytes
with increased levels of HIV DNA and those with HIV DNA integration. This rapid clearance of
HIV-infected hepatocytes partially explains low reverse transcriptase (RT) activity in cell supernatants.
In the literature, there are several very controversial reports on HIV DNA integration even in the
absence of AGS: while some authors demonstrated HIV DNA integration and low levels of productive
infection in hepatocytes [7,35], others did not support this evidence [43]. In fact, our experimental
conditions, which allow the detection of HIV DNA integration in hepatocytes in the presence of AGS,
are artificial because this phenomenon can be observed only when apoptosis in infected hepatocytes
is prevented by PCI (in vitro conditions). In vivo, we faced the depletion of HIV-exposed human
hepatocytes as a result of ethanol feeding, with a residual apoptosis after the feeding completion.
To characterize the changes induced in HIV-infected hepatocytes by ethanol exposure, we
performed NGS studies on HIV-infected vs. HIV-infected-ethanol-treated hepatocytes. Here, in
addition to up-regulation of multiple metabolic and apoptosis-associated changes in HIV-infected
hepatocytes exposed to ethanol, we observed Vpr RNA expression and an accessory viral protein known
to block innate immunity factor (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like
3G gene APOBEC3G) to potentially increase HIV infectivity [44]. In addition, we found that other
antiviral ISGs, OAS1 and ISG15, were suppressed by AGS, which was associated with activation
of pro-apoptotic genes, TRAIL-R2 and p53. However, regardless decreased innate immunity in
AGS-exposed hepatocytes, we observed no infectivity in the medium collected from HIV-infected liver
cells also exposed to AGS, indicating abortive HIV replication, which in turn, may lead to apoptosis
induction in these cells. Since HIV DNA integration is a prerequisite for HIV replication, this suggests
that Ach increases it in a small number of hepatocytes, which is visible only if these cells do not
undergo rapid apoptosis. Obviously, while exposure to Ach increases both HIV RNA and integrated
HIV DNA levels, it does not make HIV-infection productive, corresponding to the previous findings
observed in Ach-non-treated HIV-infected hepatocytes [45].
Our data provide evidence of apoptotic hepatocyte death due to accumulation of HIV components
combined with the effects of ethanol metabolism, primarily, Ach. The incomplete HIV replication
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accompanied by accumulation of HIV DNA without integration into host genome has been shown to
promote apoptosis [46]. Thus, we cannot exclude that in our study, accumulation of HIV DNA due to
abortive HIV replication in hepatocytes may serve as an additional trigger of apoptosis in the case of
cell co-exposure to HIV and AGS.
It is unlikely that accumulation of HIV in ethanol-metabolism-exposed hepatocytes is due to
an AGS-induced increase in receptors for HIV entry. Although we observed up-regulative effect of
AGS on CXCR4 receptor expression on RLW cells, it has been shown that HIVADA binds only CCR5
receptor, not CXCR4 [47,48], and thus it is very questionable whether AGS-enhanced expression of
CXCR4 would increase the entry of HIVADA (which we used here) into RLW cells.
The kinetics of HIV RNA and p24 expression in liver cells demonstrate the decrease in their
levels from day 1 to day 3 and further to day 5 post HIV-infection in AGS-exposed and non-exposed
cells. This decrease is not due to depletion of infected cells by intensive apoptosis, which in these
experiments, was prevented by co-treatment with PCI. The presence of the late HIV protein p24 at day
1–2 post-infection could be due to internalization of the viral particles in hepatocytes and prolonged p24
expression until it is degraded. In fact, lysosome was reported to participate in p24 degradation [43].
Because ethanol metabolism suppresses lysosome function and biogenesis [49], we observed higher
p24 levels in hepatocytes treated with AGS. According to our findings, both lysosome and proteasome
may contribute to p24 degradation since lysosomal and proteasome inhibitors applied at day 2 post
infection partially slowed down the degradation of p24 by day 3, mimicking the stabilizing effects
of Ach on p24 levels. The decline in cathepsin and proteasome activities by ethanol metabolism
indeed has been reported before and was linked to oxidative stress induction [32,50]. In our hands,
a combination of HIV-AGS provided in vitro down-regulative effects on cathepsin and proteasome
activities. Importantly, according to the results of kinetic experiments, there is no direct link between
HIV-specific p24 or RNA levels and increased caspase-3 cleavage, indicating that HIV components
activated oxidative stress (based on increased 4HNE protein adduct expression and ROS production),
which in turn, induced apoptosis in hepatocytes.
Induction of hepatocyte apoptosis upon exposure to HIV and ethanol was also confirmed by our
in vivo studies on humanized mice. Multiple injection of HIV in the process of ethanol feeding of
mice transplanted with human hepatocytes led to very significant depletion of human hepatocytes
judged by human albumin levels. Previously, we also observed the depletion in human albumin in
dual-reconstituted humanized mice transplanted with human hepatocytes and mismatched human
hematopoietic/progenitor cells infected with HIV [29]. However, upon ethanol feeding, significant
HIV-induced cell death (human albumin depletion) occurred even in the absence of human immune
system. The increased expression of the oxidative stress marker TBARS accompanied by the presence
of residual apoptotic cells and HIV DNA in hepatocytes as the only transplanted HIV-infectable human
cells was observed in these ethanol-fed mice.
What is the consequence of intensive hepatocyte apoptosis driven by HIV and alcohol metabolism?
Apoptosis serves as a method of HIV-infected hepatocyte elimination, but is it a truly beneficial event?
Exposure of MDM to ABs from HIV-infected hepatocytes caused activation of inflammasome, while
in HSC, it induced the activation of pro-fibrotic genes. Thus, the engulfment of ABs generated from
HIV-infected hepatocytes by non-parenchymal cells contributes to pathogenesis of HIV-infection in
the liver, suggesting that ethanol metabolism-induced apoptosis in HIV-infected hepatocytes may
promote liver inflammation and fibrosis development. These properties of ABs are pathogen and
hepatocyte-specific; however, the nature of these events is not quite clear yet. Our major in vitro
findings are summarized in Figure 10.
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5. Conclusions 
We conclude that ethanol metabolism by slowing down the degradation of HIV components by 
lysosomes and proteasomes causes accumulation of HIV patterns in hepatocytes to induce oxidative 
stress and apoptotic cell death. Clearance of these HIV-infected apoptotic bodies by liver non-
parenchymal cells promotes inflammasome activation in macrophages and pro-fibrotic gene 
activation in hepatic stellate cells, thereby contributing to liver disease progression. 
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Figure 10. Ethanol metabolism promotes apoptosis in HIV-infected hepatocytes, causing liver
inflammation and fibrosis development. Ethanol metabolism suppresses lysosome and proteasome
activities in HIV-infected hepatocytes and causes accumulation of HIV components, finally leading
to apoptosis induction and abortive HIV replication. Apoptotic hepatocytes that contain viral
components are engulfed by macrophages (MDMs) and HSCs, thereby promoting activation of
inflammasome in MDMs and activation of pro-fibrotic genes in HSCs, leading to liver inflammation
and fibrosis development.
5. Conclusions
We conclude that ethanol metabolism by slowing down the degradation of HIV components
by lysosomes and proteasomes causes accumulation of HIV patterns in hepatocytes to induce
oxidative stress and apoptotic cell death. Clearance of these HIV-infected apoptotic bodies by liver
non-parenchymal cells promotes inflammasome activation in macrophages and pro-fibrotic gene
activation in hepatic stellate cells, thereby contributing to liver disease progression.
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